ALN-AT3 regulatory update

Alnylam said FDA granted Orphan Drug designation for ALN-AT3 to treat hemophilia B. The subcutaneous RNAi therapeutic targeting anti-thrombin III (AT3; SERPINC1) mRNA is in preclinical testing to tr...